The authors concluded that co-treatment with GnRH agonists during chemotherapy was associated with increased odds of preserving a woman's ovarian function and increased chance of pregnancy following treatment. This review is likely to be vulnerable to several sources of bias and the results should not be considered as reliable.
Study selection
Eligible studies were controlled studies that compared females under 50 years who underwent potentially ovarian-toxic therapy for treatment of malignancy or rheumatology disease. Comparison was between those who received GnRHa and a similar control group that did not receive GnRHa. Relevant ovarian function outcomes were menstrual history, folliclestimulating hormone levels (FSH) or antral follicle counts. Pregnancy rates were eligible as a measure of fertility.
Included in this review was a mixture of randomised and non-randomised controlled studies conducted in Israel, Spain, Italy, Argentina, UK and USA. Six studies included women who underwent chemotherapy for lymphoma or leukemia. Three studies included women who were treated with cyclophosphamide (CYC) for severe lupus. Doses of GnRHa were similar across most of the studies (around 3.75mg every four weeks) and given either two weeks prior to chemotherapy or with a short-acting GnRHa. Three types of GnRHa were used: two were given intramuscularly (leuprolide, triptorelin); and one was given nasally (buserelin). Most studies reported regular menses after chemotherapy to indicate ovarian function among other measures. Patient follow-up ranged from two to 17 years.
Studies were selected by two reviewers.
Assessment of study quality
It appeared that randomisation method and length of follow-up period were considered.
The authors did not report how many reviewers performed the validity assessment.
Data extraction
Data were extracted from each study into contingency tables to allow the calculation of relative risks (RR) for ovarian preservation and relative risks of pregnancy following chemotherapy (based on number of initial pregnancies during follow-up).
The authors did not report how many reviewers carried out data extraction.
Methods of synthesis
Meta-analysis was used to calculate summary relative risks and 95% confidence intervals (CI) for the outcomes of interest. Heterogeneity was tested using Χ 2 tests. Where significant heterogeneity was present, a random-effects model was used in preference to a fixed-effect model. The fixed-effect model used a variance-weighted method and the random-effects model used an empirical Bayes or restricted likelihood estimation method. Where studies reported no
